Zenas BioPharma Statistics

Total Valuation

Zenas BioPharma has a market cap or net worth of $341.50 million. The enterprise value is -$8.26 million.

Market Cap	341.50M
Enterprise Value	-8.26M

Important Dates

The next estimated earnings date is Friday, May 16, 2025, before market open.

Earnings Date	May 16, 2025
Ex-Dividend Date	n/a

Share Statistics

Zenas BioPharma has 41.80 million shares outstanding. The number of shares has increased by 762.01% in one year.

Current Share Class	41.80M
Shares Outstanding	41.80M
Shares Change (YoY)	+762.01%
Shares Change (QoQ)	+444.73%
Owned by Insiders (%)	0.97%
Owned by Institutions (%)	52.88%
Float	23.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.57
Forward PS	n/a
PB Ratio	1.09
P/TBV Ratio	1.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.21, with a Debt / Equity ratio of 0.00.

Current Ratio	6.21
Quick Ratio	6.12
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -93.22% and return on invested capital (ROIC) is -57.07%.

Return on Equity (ROE)	-93.22%
Return on Assets (ROA)	-46.76%
Return on Invested Capital (ROIC)	-57.07%
Return on Capital Employed (ROCE)	-52.41%
Revenue Per Employee	$38,462
Profits Per Employee	-$1.21M
Employee Count	130
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

In the past 12 months, Zenas BioPharma has paid $429,000 in taxes.

Income Tax	429,000
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	7.62
200-Day Moving Average	n/a
Relative Strength Index (RSI)	51.68
Average Volume (20 Days)	191,799

Short Selling Information

The latest short interest is 3.47 million, so 8.30% of the outstanding shares have been sold short.

Short Interest	3.47M
Short Previous Month	3.30M
Short % of Shares Out	8.30%
Short % of Float	15.01%
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zenas BioPharma had revenue of $5.00 million and -$156.99 million in losses. Loss per share was -$11.89.

Revenue	5.00M
Gross Profit	-134.14M
Operating Income	-163.89M
Pretax Income	-54.46M
Net Income	-156.99M
EBITDA	-163.75M
EBIT	-163.89M
Loss Per Share	-$11.89

Full Income Statement

Balance Sheet

The company has $350.77 million in cash and $1.00 million in debt, giving a net cash position of $349.76 million or $8.37 per share.

Cash & Cash Equivalents	350.77M
Total Debt	1.00M
Net Cash	349.76M
Net Cash Per Share	$8.37
Equity (Book Value)	312.46M
Book Value Per Share	7.48
Working Capital	298.63M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$119.67 million and capital expenditures -$131,000, giving a free cash flow of -$119.81 million.

Operating Cash Flow	-119.67M
Capital Expenditures	-131,000
Free Cash Flow	-119.81M
FCF Per Share	-$2.87

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-3,277.76%
Pretax Margin	-3,131.18%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Zenas BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-762.01%
Shareholder Yield	n/a
Earnings Yield	-45.97%
FCF Yield	-35.08%

Dividend Details

Analyst Forecast

The average price target for Zenas BioPharma is $32.29, which is 295.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$32.29
Price Target Difference	295.23%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zenas BioPharma has an Altman Z-Score of 4.79 and a Piotroski F-Score of 2.

Altman Z-Score	4.79
Piotroski F-Score	2